Literature DB >> 19536121

Biomarkers in clinical drug development.

J V S Gobburu1.   

Abstract

The primary purpose of this Commentary is to complement the description of biomarkers given in this issue in the Pharmaceutical Research and Manufacturers of America report by Lathia et al. I offer several examples of the use of biomarkers that highlight their value in drug development and regulatory decision making.

Mesh：

Substances：

Year:  2009        PMID： 19536121     DOI： 10.1038/clpt.2009.57

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  6 in total

1.  Viewing the elephant from 200 feet: reconstructing the schizophrenia syndrome.

Authors:  John A Sweeney
Journal:  Schizophr Res       Date:  2011-02-01       Impact factor: 4.939

Review 2.  The application of biomarkers in clinical trials for motor neuron disease.

Authors:  Jeban Ganesalingam; Robert Bowser
Journal:  Biomark Med       Date:  2010-04       Impact factor: 2.851

Review 3.  Biomarkers and surrogate endpoints in glaucoma clinical trials.

Authors:  Felipe A Medeiros
Journal:  Br J Ophthalmol       Date:  2014-07-17       Impact factor: 4.638

4.  Drug Development and Potential Regulatory Paths for Insulin Biosimilars.

Authors:  Mukul Minocha; Jogarao Gobburu
Journal:  J Diabetes Sci Technol       Date:  2014-01-01

5.  Drug development in pediatric psychiatry: current status, future trends.

Authors:  John S March; Joerg M Fegert
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2012-02-07       Impact factor: 3.033

Review 6.  Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma.

Authors:  Felipe A Medeiros
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-05-01       Impact factor: 4.799
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.